Arcellx, Inc. (ACLX)

115.05 -0.05 (-0.04%) USD  |  NASDAQ  |  Apr 17, 16:00
115.07 +0.02 (+0.02%) After-Hours: 20:00
More

Arcellx SG&A Expense (Quarterly) : 31.24M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for ACLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 4.418B
Eli Lilly & Co. 3.132B
Merck & Co., Inc. 2.898B
Bristol Myers Squibb Co. 2.181B
BioMarin Pharmaceutical, Inc. 446.21M